Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer

Journal of Immunology

Volumn 191, Issue 4, 2013, Pages 1509-1515

  El Gazzar, Ahmed ^a   Groh, Veronika ^a   Spies, Thomas ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; LIGAND; MICRORNA; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND; UNCLASSIFIED DRUG;

CANCER CELL; CANCER IMMUNOLOGY; CANCER SURVIVAL; COMPLEMENT SYSTEM; HUMAN; IMMUNE EVASION; IMMUNOBIOLOGY; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH;

ANIMALS; AUTOCRINE COMMUNICATION; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE PROGRESSION; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE;

EID: 84881413925     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301071     Document Type: Review

References (67)

1. Nausch, N., and A. Cerwenka. 2008. NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958.
2. + T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206: 793-805.
3. González, S., A. López-Soto, B. Suarez-Alvarez, A. López-Vázquez, and C. López-Larrea. 2008. NKG2D ligands: key targets of the immune response. Trends Immunol. 29: 397-403.
4. Raulet, D. H., S. Gasser, B. G. Gowen, W. Deng, and H. Jung. 2013. Regulation of ligands for the NKG2D activating receptor. Annu. Rev. Immunol. 31: 413-441.
5. González, S., V. Groh, and T. Spies. 2006. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 298: 121-138.
6. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502.
7. Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagat, T. N. Krausz, D. H. Raulet, L. L. Lanier, V. Groh, T. Spies, et al. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21: 357-366.
8. Upshaw, J. L., and P. J. Leibson. 2006. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin. Immunol. 18: 167-175.
9. + T cells. J. Immunol. 174: 4480-4484.
10. + T cells. J. Immunol. 176: 1490-1497.
11. c cytokines and TGF-β1. Blood 118: 3019-3027.
12. Krockenberger, M., Y. Dombrowski, C. Weidler, M. Ossadnik, A. Hönig, S. Häusler, H. Voigt, J. C. Becker, L. Leng, A. Steinle, et al. 2008. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J. Immunol. 180: 7338-7348.
13. Eagle, R. A., and J. Trowsdale. 2007. Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7: 737-744.
14. Eleme, K., S. B. Taner, B. Onfelt, L. M. Collinson, F. E. McCann, N. J. Chalupny, D. Cosman, C. Hopkins, A. I. Magee, and D. M. Davis. 2004. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 199: 1005-1010.
15. Steinle, A., P. Li, D. L. Morris, V. Groh, L. L. Lanier, R. K. Strong, and T. Spies. 2001. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics 53: 279-287.
16. Li, P., D. L. Morris, B. E. Willcox, A. Steinle, T. Spies, and R. K. Strong. 2001. Complex structure of the activating immunoreceptor NKG2D and its MHC class Ilike ligand MICA. Nat. Immunol. 2: 443-451.
17. Radaev, S., B. Rostro, A. G. Brooks, M. Colonna, and P. D. Sun. 2001. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 15: 1039-1049.
18. Champsaur, M., and L. L. Lanier. 2010. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235: 267-285.
19. Stern-Ginossar, N., C. Gur, M. Biton, E. Horwitz, M. Elboim, N. Stanietsky, M. Mandelboim, and O. Mandelboim. 2008. Human microRNAs regulate stressinduced immune responses mediated by the receptor NKG2D. Nat. Immunol. 9: 1065-1073.
20. Hilpert, J., L. Grosse-Hovest, F. Grünebach, C. Buechele, T. Nuebling, T. Raum, A. Steinle, and H. R. Salih. 2012. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J. Immunol. 189: 1360-1371.
21. Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178: 961-969.
22. Nausch, N., L. Florin, B. Hartenstein, P. Angel, M. Schorpp-Kistner, and A. Cerwenka. 2006. Cutting edge: the AP-1 subunit JunB determines NK cellmediated target cell killing by regulation of the NKG2D-ligand RAE-1ε. J. Immunol. 176: 7-11.
23. Textor, S., N. Fiegler, A. Arnold, A. Porgador, T. G. Hofmann, and A. Cerwenka. 2011. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 71: 5998-6009.
24. Boissel, N., D. Rea, V. Tieng, N. Dulphy, M. Brun, J. M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F. X. Mahon, et al. 2006. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176: 5108-5116.
25. Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190.
26. Chen, Z., L. Chen, K. Baker, T. Olszak, S. Zeissig, Y. H. Huang, T. T. Kuo, O. Mandelboim, N. Beauchemin, L. L. Lanier, and R. S. Blumberg. 2011. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J. Exp. Med. 208: 2633-2640.
27. Tsuboi, S., M. Sutoh, S. Hatakeyama, N. Hiraoka, T. Habuchi, Y. Horikawa, Y. Hashimoto, T. Yoneyama, K. Mori, T. Koie, et al. 2011. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30: 3173-3185.
28. Heinemann, A., F. Zhao, S. Pechlivanis, J. Eberle, A. Steinle, S. Diederichs, D. Schadendorf, and A. Paschen. 2012. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 72: 460-471.
29. Volinia, S., G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA 103: 2257-2261.
30. Dahiya, N., C. A. Sherman-Baust, T. L. Wang, B. Davidson, IeM. Shih, Y. Zhang, W. Wood, III, K. G. Becker, and P. J. Morin. 2008. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE 3: e2436.
31. Li, Y., W. Tan, T. W. Neo, M. O. Aung, S. Wasser, S. G. Lim, and T. M. Tan. 2009. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci. 100: 1234-1242.
32. Huang, Q., K. Gumireddy, M. Schrier, C. le Sage, R. Nagel, S. Nair, D. A. Egan, A. Li, G. Huang, A. J. Klein-Szanto, et al. 2008. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10: 202-210.
33. Guerra, N., Y. X. Tan, N. T. Joncker, A. Choy, F. Gallardo, N. Xiong, S. Knoblaugh, D. Cado, N. M. Greenberg, and D. H. Raulet. 2008. NKG2Ddeficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28: 571-580.
34. Hayashi, T., K. Imai, Y. Morishita, I. Hayashi, Y. Kusunoki, and K. Nakachi. 2006. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 66: 563-570.
35. Furue, H., H. Kumimoto, K. Matsuo, T. Suzuki, Y. Hasegawa, M. Shinoda, T. Sugimura, K. Mitsudo, I. Tohnai, M. Ueda, et al. 2008. Opposite impact of NKG2D genotype by lifestyle exposure to risk of aerodigestive tract cancer among Japanese. Int. J. Cancer 123: 181-186.
36. Furue, H., K. Matsuo, H. Kumimoto, A. Hiraki, T. Suzuki, Y. Yatabe, K. Komori, Y. Kanemitsu, T. Hirai, T. Kato, et al. 2008. Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis 29: 316-320.
37. 72Ala polymorphism in patients with cervical carcinoma. Genet. Test. Mol. Biomarkers 16: 841-845.
38. McGilvray, R. W., R. A. Eagle, N. F. Watson, A. Al-Attar, G. Ball, I. Jafferji, J. Trowsdale, and L. G. Durrant. 2009. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin. Cancer Res. 15: 6993-7002.
39. Duan, X., L. Deng, X. Chen, Y. Lu, Q. Zhang, K. Zhang, Y. Hu, J. Zeng, and W. Sun. 2011. Clinical significance of the immunostimulatory MHC class I chainrelated molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med. Oncol. 28: 466-474.
40. de Kruijf, E. M., A. Sajet, J. G. van Nes, H. Putter, V. T. Smit, R. A. Eagle, I. Jafferji, J. Trowsdale, G. J. Liefers, C. J. van de Velde, and P. J. Kuppen. 2012. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. BMC Cancer 12: 24-35.
41. Groh, V., J. Wu, C. Yee, and T. Spies. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738.
42. Doubrovina, E. S., M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas. 2003. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171: 6891-6899.
43. Clayton, A., J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi. 2008. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 180: 7249-7258.
44. Wu, J. D., C. L. Atteridge, X. Wang, T. Seya, and S. R. Plymate. 2009. Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin. Cancer Res. 15: 632-640.
45. Jinushi, M., F. S. Hodi, and G. Dranoff. 2006. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc. Natl. Acad. Sci. USA 103: 9190-9195.
46. Wu, J. D., L. M. Higgins, A. Steinle, D. Cosman, K. Haugk, and S. R. Plymate. 2004. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114: 560-568.
47. Li, K., M. Mandai, J. Hamanishi, N. Matsumura, A. Suzuki, H. Yagi, K. Yamaguchi, T. Baba, S. Fujii, and I. Konishi. 2009. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol. Immunother. 58: 641-652.
48. Paschen, A., A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al. 2009. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res. 15: 5208-5215.
49. Rebmann, V., P. Schütt, D. Brandhorst, B. Opalka, T. Moritz, M. R. Nowrousian, and H. Grosse-Wilde. 2007. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin. Immunol. 123: 114-120.
50. Kaiser, B. K., D. Yim, I. T. Chow, S. Gonzalez, Z. Dai, H. H. Mann, R. K. Strong, V. Groh, and T. Spies. 2007. Disulphide-isomerase-enabled shedding of tumourassociated NKG2D ligands. Nature 447: 482-486.
51. Jinushi, M., M. Vanneman, N. C. Munshi, Y. T. Tai, R. H. Prabhala, J. Ritz, D. Neuberg, K. C. Anderson, D. R. Carrasco, and G. Dranoff. 2008. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. USA 105: 1285-1290.
52. Huergo-Zapico, L., A. P. Gonzalez-Rodriguez, J. Contesti, E. Gonzalez, A. López-Soto, A. Fernandez-Guizan, A. Acebes-Huerta, J. R. de Los Toyos, C. Lopez-Larrea, V. Groh, et al. 2012. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol. Immunother. 61: 1201-1210.
53. Agüera-González, S., C. C. Gross, L. Fernández- Messina, O. Ashiru, G. Esteso, H. C. Hang, H. T. Reyburn, E. O. Long, and M. Valés-Gómez. 2011. Palmitoylation of MICA, a ligand for NKG2D, mediates its recruitment to membrane microdomains and promotes its shedding. Eur. J. Immunol. 41: 3667-3676.
54. Waldhauer, I., D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H. G. Rammensee, and A. Steinle. 2008. Tumorassociated MICA is shed by ADAM proteases. Cancer Res. 68: 6368-6376.
55. Garcia-Iglesias, T., A. Del Toro-Arreola, B. Albarran-Somoza, S. Del Toro-Arreola, P. E. Sanchez-Hernandez, M. G. Ramirez-Dueñas, L. M. Balderas-Peña, A. Bravo-Cuellar, P. C. Ortiz-Lazareno, and A. Daneri-Navarro. 2009. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9: 186-193.
56. Baniyash, M. 2004. TCR ξ-chain downregulation: curtailing an excessive inflammatory immune response. Nat. Rev. Immunol. 4: 675-687.
57. Hanaoka, N., B. Jabri, Z. Dai, C. Ciszewski, A. M. Stevens, C. Yee, H. Nakakuma, T. Spies, and V. Groh. 2010. NKG2D initiates caspase-mediated CD3ξ degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J. Immunol. 185: 5732-5742.
58. Groh, V., K. Smythe, Z. Dai, and T. Spies. 2006. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat. Immunol. 7: 755-762.
59. Benitez, A. C., Z. Dai, H. H. Mann, R. S. Reeves, D. H. Margineantu, T. A. Gooley, V. Groh, and T. Spies. 2011. Expression, signaling proficiency, and stimulatory function of the NKG2D lymphocyte receptor in human cancer cells. Proc. Natl. Acad. Sci. USA 108: 4081-4086.
60. Normanno, N., A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M. R. Maiello, A. Carotenuto, G. De Feo, F. Caponigro, and D. S. Salomon. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
61. Krieg, S., and E. Ullrich. 2012. Novel immune modulators used in hematology: impact on NK cells. Front. Immunol. 3: 388-397.
62. von Strandmann, E. P., H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al. 2006. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 107: 1955-1962.
63. Cho, H. M., J. D. Rosenblatt, K. Tolba, S. J. Shin, D. S. Shin, C. Calfa, Y. Zhang, and S. U. Shin. 2010. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res. 70: 10121-10130.
64. Zhang, T., and C. L. Sentman. 2011. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 71: 2066-2076.
65. Zhang, B., S. Kracker, T. Yasuda, S. Casola, M. Vanneman, C. Hömig-Hölzel, Z. Wang, E. Derudder, S. Li, T. Chakraborty, et al. 2012. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148: 739-751.
66. Lehner, M., G. Götz, J. Proff, N. Schaft, J. Dörrie, F. Full, A. Ensser, Y. A. Muller, A. Cerwenka, H. Abken, et al. 2012. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS ONE 7: e31210.
67. Song, D. G., Q. Ye, S. Santoro, C. Fang, A. Best, and D. J. Powell, Jr. 2013. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum. Gene Ther. 24: 295-305.